Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

A Case of Tardive Dyskinesia and Parkinsonism Following Use of Phentermine for Weight Loss (P4.082)

Ryan Barmore, Christopher Hess, Nikolaus McFarland, Michael Okun
First published April 9, 2018,
Ryan Barmore
1UF Center for Movement Disorders & Neurorestoration Gainesville FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Hess
1UF Center for Movement Disorders & Neurorestoration Gainesville FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaus McFarland
2University of Florida Gainesville FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Okun
2University of Florida Gainesville FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Case of Tardive Dyskinesia and Parkinsonism Following Use of Phentermine for Weight Loss (P4.082)
Ryan Barmore, Christopher Hess, Nikolaus McFarland, Michael Okun
Neurology Apr 2018, 90 (15 Supplement) P4.082;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To report a case of phentermine-induced tardive dyskinesia and parkinsonism.

Background: Tardive dyskinesia is a movement disorder characterized by the delayed onset of involuntary muscle movements usually following use of dopaminergic antagonists. It can be associated with several other classes of medications including both prescribed and illicit stimulants. Phentermine is an amphetamine that is approved for weight loss but only with short-term use.

Design/Methods: Case report and review of the literature.

Results: We present the case of a 56-year-old man with a history of depression and obesity who presented with the complaint of unilateral tremor and tongue thrusting. He was on no medication. On exam, his mental status was notable only for impaired delayed recall. He had repetitive tongue thrusts, of which he was unaware. He had a 4–6 Hz resting tremor in his right hand. He had mild bradykinesia and rigidity in his right upper extremity. He had normal strength and sensation throughout. He had no axial or appendicular ataxia. His gait was normal and he had no retropulsion on pull testing. A MRI brain was normal. He had no history of dopamine replacement or dopamine antagonist use. His father had Parkinson’s disease but it occurred late in life. His tongue thrusting and rest tremor had arisen following a two-month trial of phentermine which was prescribed for weight loss.

Conclusions: This is the second report of a tardive syndrome arising in the setting of phentermine use. Phentermine is an amphetamine and can lead to dopamine depletion. This case illustrates the potential for tardive syndromes associated with stimulant use. While atypical, it is important to recognize the potential occurrence of this side effect. Additionally, it is possible that his parkinsonism represented either an unmasking of idiopathic Parkinson’s disease or a drug-induced phenomenon. We will discuss diagnostic possibilities and treatment of these movement disorders.

Disclosure: Dr. Barmore has nothing to disclose. Dr. Hess has nothing to disclose. Dr. McFarland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Okun has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with National Parkinson Foundation, Medscape, Mededicus.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Dr. Jessica Ailani and Dr. Ailna Masters-Israilov

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (23)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise